ARNA Arena Pharmaceuticals Inc.

27.56
+0.71  (3%)
Previous Close 26.85
Open 27.11
Price To book 13.06
Market Cap 1080909952
Shares 39,220,245
Volume 759,648
Short Ratio 4.67
Av. Daily Volume 512,966

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014767
  2. 8-K - Current report 171011488
  3. 8-K - Current report 17963701
  4. 424B5 - Prospectus [Rule 424(b)(5)] 17963680
  5. 8-K - Current report 17960526

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 to be initiated 2017.
Etrasimod
Primary biliary cholangitis (PBC)
Phase 2 trial initiated March 2017.
Etrasimod
Pyoderma gangrenosum (PG)
Phase 2 trial initiated March 2017.
Etrasimod
Dermatological extraintestinal manifestations (EIM) in patients with inflammatory bowel disease (IBD)
Approved June 27, 2012.
Lorcaserin
Obesity
Phase 2 data due year-end 2017 or 1Q 2018.
APD371
Pain associated with Crohn's disease
Phase 2 initiated March 2014. Data released Nov 2014
Lorcaserin
Smoking cessation
Phase 2 data due by end of 2017 or 1Q 2018.
Etrasimod
Ulcerative colitis
Phase 2 data released July 10, 2017. Primary endpoint met. Secondary missed.
Ralinepag
Pulmonary Arterial Hypertension

Latest News

  1. ETFs with exposure to Arena Pharmaceuticals, Inc. : October 17, 2017
  2. Do This 1 Thing and Lower Your Risk for 13 Types of Cancer
  3. Here's What Lifted Arena Pharmaceuticals, Inc. Stock in September
  4. One Thing To Consider Before Buying Arena Pharmaceuticals Inc (ARNA)
  5. Orexigen's (OREX) Contrave Sales Improving on Promotions
  6. ETFs with exposure to Arena Pharmaceuticals, Inc. : September 22, 2017
  7. Edited Transcript of ARNA earnings conference call or presentation 7-Aug-17 8:30pm GMT
  8. Intercept Pharmaceuticals Inc (ICPT) Stock Dives on Drug Warning
  9. Cramer's lightning round: Allergan's in a torturous situa...
  10. Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 8, 2017
  11. Arena Pharmaceuticals (ARNA) Down 1.5% Since Earnings Report: Can It Rebound?
  12. Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at International Congress of the European Respiratory Society
  13. Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
  14. Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : August 23, 2017
  15. Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at European Society of Cardiology Congress
  16. The 1 Very Clear Reason Arena Pharmaceuticals, Inc. Skyrocketed 41% in July
  17. Arena Pharmaceuticals (ARNA) Q2 Loss Wider than Expected
  18. Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and Opko Health